S Vincent Rajkumar
S Vincent Rajkumar
Multiple myeloma (MM) is a plasma cell malignancy historically defined by the presence of end-organ damage, specifically, hypercalcemia, renal failure, anemia, and bone lesions (CRAB features) that can be attributed to the neoplastic proces...
What's different about atypical CML and chronic neutrophilic leukemia? [0.03%]
.atypical CML和慢性中性粒细胞白血病有什么不同？
Kim-Hien T Dao,Jeffrey W Tyner
Kim-Hien T Dao
Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare myeloid neoplasms defined largely by morphologic criteria. The discovery of CSF3R mutations in aCML and CNL have prompted a more comprehensive genetic...
Molecular monitoring in CML and the prospects for treatment-free remissions [0.03%]
慢性粒细胞白血病的分子监测及停药缓解前景
Michael W Deininger
Michael W Deininger
Monitoring treatment responses in chronic myeloid leukemia (CML) is based on complete blood counts (CBCs) to determine hematologic response, karyotyping of bone marrow metaphase cells to delineate cytogenetic response and quantitative rever...
Richard A Larson
Richard A Larson
The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has dramatically improved the outcomes for patients with every stage of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Clinicians n...
Jody L Kujovich
Jody L Kujovich
Liver disease results in complex alterations of all 3 phases of hemostasis. It is now recognized that hemostasis is rebalanced in chronic liver disease. The fall in clotting factor levels is accompanied by a parallel fall in anticoagulant p...
Donald M Arnold
Donald M Arnold
Bleeding manifestations in patients with immune thrombocytopenia (ITP) range from mild skin bruises to life-threatening intracranial hemorrhage (ICH). Severe bleeding is distinctly uncommon when the platelet count is >30 × 10(9)/L and usua...
Rebecca Kruse-Jarres
Rebecca Kruse-Jarres
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow....
Robert S Negrin
Robert S Negrin
Graft-versus-host disease (GVHD) is a significant clinical problem after allogenic hematopoietic cell transplantation (HCT) associated with substantial morbidity and mortality that limits the potential utility of transplantation. Associated...
Claudio Anasetti
Claudio Anasetti
For patients without a human leukocyte antigen (HLA)-matched sibling or unrelated donor, options include transplantation from HLA-mismatched related donors, HLA-mismatched unrelated donors, or unrelated cord blood units. Graft failure remai...
Marcel R M van den Brink,Enrico Velardi,Miguel-Angel Perales
Marcel R M van den Brink